Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.
Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorders, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.
Currently, the investigational, off-the-shelf CAR T-cell therapies ALLO-715 and ALLO-647 are being evaluated in clinical trials for patients with relapsed/refractory multiple myeloma. If these studies yield positive findings, allogeneic CAR T-cell therapies could offer a novel treatment approach for patients with relapsed/refractory multiple myeloma who have progressed on proteasome inhibitors, immunomodulatory agents, and CD38-directed antibodies.
Additionally, these products could offer more flexibility with regard to bridging therapy for CAR T-cell therapy, Usmani says. However, the overall utility of these products will depend on the capacity transplant and cellular therapy centers have to administer them, Usmani says. With bispecific antibodies also emerging in this space, more data are needed to inform how allogeneic CAR T-cell products could be integrated into clinical practice, Usmani concludes.